No Significant Changes to Residual Viremia After Switch to Dolutegravir and Lamivudine in a Randomized Trial.
ART simplification
ART switch
dolutegravir
lamivudine
residual viremia
Journal
Open forum infectious diseases
ISSN: 2328-8957
Titre abrégé: Open Forum Infect Dis
Pays: United States
ID NLM: 101637045
Informations de publication
Date de publication:
Mar 2019
Mar 2019
Historique:
received:
04
01
2019
accepted:
07
02
2019
entrez:
22
3
2019
pubmed:
22
3
2019
medline:
22
3
2019
Statut:
epublish
Résumé
In the ASPIRE trial, antiretroviral therapy (ART) switch to dolutegravir plus lamivudine (DTG+3TC) was comparable to 3-drug ART in maintaining viral suppression by standard viral load assays. We used an ultrasensitive assay to assess whether this switch led to increased residual viremia. At entry, levels of residual viremia did not differ significantly between arms (DTG+3TC vs 3-drug ART: mean, 5.0 vs 4.2 HIV-1 RNA copies/mL;
Identifiants
pubmed: 30895201
doi: 10.1093/ofid/ofz056
pii: ofz056
pmc: PMC6419983
doi:
Types de publication
Journal Article
Langues
eng
Pagination
ofz056Subventions
Organisme : NIAID NIH HHS
ID : P30 AI050409
Pays : United States
Organisme : NIAID NIH HHS
ID : UM1 AI069412
Pays : United States
Références
J Clin Microbiol. 2003 Oct;41(10):4531-6
pubmed: 14532178
J Infect Dis. 2013 Jun 1;207(11):1694-702
pubmed: 23460751
AIDS. 2014 Jan 14;28(2):181-186
pubmed: 24361679
Ann Intern Med. 2014 Sep 2;161(5):319-27
pubmed: 25047577
J Clin Microbiol. 2014 Nov;52(11):3944-51
pubmed: 25187636
AIDS. 2014 Nov 28;28(18):2649-57
pubmed: 25254301
AIDS. 2015 Apr 24;29(7):853-6
pubmed: 25719828
Open Forum Infect Dis. 2015 Jan 13;2(1):ofu117
pubmed: 25884005
AIDS. 2016 Jan 28;30(3):343-53
pubmed: 26588174
Clin Infect Dis. 2016 Mar 15;62(6):784-91
pubmed: 26658053
BMC Infect Dis. 2017 Mar 16;17(1):215
pubmed: 28302065
J Antimicrob Chemother. 2017 Jul 1;72(7):2055-2059
pubmed: 28333353
Clin Infect Dis. 2017 Nov 29;65(12):2112-2118
pubmed: 29020293
Clin Infect Dis. 2018 May 17;66(11):1689-1697
pubmed: 29253097
Clin Infect Dis. 2018 May 17;66(11):1794-1797
pubmed: 29293895
Lancet. 2018 Mar 3;391(10123):839-849
pubmed: 29310899
HIV Med. 2018 Mar 24;:null
pubmed: 29573320
J Antimicrob Chemother. 2018 Jul 1;73(7):1965-1971
pubmed: 29608685
J Antimicrob Chemother. 2018 Jul 1;73(7):1955-1964
pubmed: 29668978
J Antimicrob Chemother. 2018 Jul 1;73(7):1949-1954
pubmed: 29788156
J Clin Invest. 2018 Jul 2;128(7):3102-3115
pubmed: 29911997
BMC Infect Dis. 2018 Jun 25;18(1):285
pubmed: 29940869
Ann Oncol. 2018 Oct 1;29(10):2141-2142
pubmed: 30032204
J Acquir Immune Defic Syndr. 2018 Dec 15;79(5):e112-e114
pubmed: 30383591
Lancet. 2019 Jan 12;393(10167):143-155
pubmed: 30420123